382 related articles for article (PubMed ID: 32192573)
1. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Davis KL; Fox E; Merchant MS; Reid JM; Kudgus RA; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
Lancet Oncol; 2020 Apr; 21(4):541-550. PubMed ID: 32192573
[TBL] [Abstract][Full Text] [Related]
2. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial.
Cytryn SL; Moy RH; Cowzer D; Shah RH; Chou JF; Joshi SS; Ku GY; Maron SB; Desai A; Yang J; Sugarman R; Rao D; Goldberg Z; Charalambous C; Lapshina M; Antoine A; Socolow F; Trivedi N; Capanu M; Gerdes H; Schattner MA; Simmons M; Lacouture ME; Paroder V; Tang LH; Shia J; Ilson DH; Solit DB; Berger MF; Janjigian YY
Lancet Oncol; 2023 Oct; 24(10):1073-1082. PubMed ID: 37666264
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213).
Norris RE; Fox E; Reid JM; Ralya A; Liu XW; Minard C; Weigel BJ
Pediatr Blood Cancer; 2018 May; 65(5):e26944. PubMed ID: 29292843
[TBL] [Abstract][Full Text] [Related]
4. A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614).
Greengard E; Williams R; Moriarity B; Liu X; Minard CG; Reid JM; Fisher T; Evans E; Pastore DR; Zauderer M; Voss S; Fox E; Weigel BJ
Pediatr Blood Cancer; 2024 Jun; 71(6):e30938. PubMed ID: 38520670
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
Santin AD; Deng W; Frumovitz M; Buza N; Bellone S; Huh W; Khleif S; Lankes HA; Ratner ES; O'Cearbhaill RE; Jazaeri AA; Birrer M
Gynecol Oncol; 2020 Apr; 157(1):161-166. PubMed ID: 31924334
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group.
Weigel B; Malempati S; Reid JM; Voss SD; Cho SY; Chen HX; Krailo M; Villaluna D; Adamson PC; Blaney SM
Pediatr Blood Cancer; 2014 Mar; 61(3):452-6. PubMed ID: 23956055
[TBL] [Abstract][Full Text] [Related]
7. Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors.
Kubo T; Ninomiya T; Hotta K; Kozuki T; Toyooka S; Okada H; Fujiwara T; Udono H; Kiura K
Clin Lung Cancer; 2018 Nov; 19(6):e861-e864. PubMed ID: 30172698
[TBL] [Abstract][Full Text] [Related]
8. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.
Olmos D; Postel-Vinay S; Molife LR; Okuno SH; Schuetze SM; Paccagnella ML; Batzel GN; Yin D; Pritchard-Jones K; Judson I; Worden FP; Gualberto A; Scurr M; de Bono JS; Haluska P
Lancet Oncol; 2010 Feb; 11(2):129-35. PubMed ID: 20036194
[TBL] [Abstract][Full Text] [Related]
9. CX-072 (pacmilimab), a Probody
Naing A; Thistlethwaite F; De Vries EGE; Eskens FALM; Uboha N; Ott PA; LoRusso P; Garcia-Corbacho J; Boni V; Bendell J; Autio KA; Randhawa M; Durm G; Gil-Martin M; Stroh M; Hannah AL; Arkenau HT; Spira A
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301809
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.
Malempati S; Weigel B; Ingle AM; Ahern CH; Carroll JM; Roberts CT; Reid JM; Schmechel S; Voss SD; Cho SY; Chen HX; Krailo MD; Adamson PC; Blaney SM
J Clin Oncol; 2012 Jan; 30(3):256-62. PubMed ID: 22184397
[TBL] [Abstract][Full Text] [Related]
11. First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.
Cole CB; Morelli MP; Fantini M; Miettinen M; Fetsch P; Peer C; Figg WD; Yin T; Houston N; McCoy A; Lipkowitz S; Zimmer A; Lee JM; Pavelova M; Villanueva EN; Trewhitt K; Solarz BB; Fergusson M; Mavroukakis SA; Zaki A; Tsang KY; Arlen PM; Annunziata CM
J Exp Clin Cancer Res; 2023 Mar; 42(1):76. PubMed ID: 36991390
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors.
Pilbeam KL; Pradhan K; Croop J; Minard CG; Liu X; Voss SD; Isikwei E; Berg SL; Reid JM; Fox E; Weigel BJ
Pediatr Blood Cancer; 2024 Mar; 71(3):e30817. PubMed ID: 38189770
[TBL] [Abstract][Full Text] [Related]
13. A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory
Kieran MW; Geoerger B; Dunkel IJ; Broniscer A; Hargrave D; Hingorani P; Aerts I; Bertozzi AI; Cohen KJ; Hummel TR; Shen V; Bouffet E; Pratilas CA; Pearson ADJ; Tseng L; Nebot N; Green S; Russo MW; Whitlock JA
Clin Cancer Res; 2019 Dec; 25(24):7294-7302. PubMed ID: 31506385
[TBL] [Abstract][Full Text] [Related]
14. Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial.
Thompson EM; Landi D; Brown MC; Friedman HS; McLendon R; Herndon JE; Buckley E; Bolognesi DP; Lipp E; Schroeder K; Becher OJ; Friedman AH; McKay Z; Walter A; Threatt S; Jaggers D; Desjardins A; Gromeier M; Bigner DD; Ashley DM
Lancet Child Adolesc Health; 2023 Jul; 7(7):471-478. PubMed ID: 37004712
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).
Kim JW; Lee HJ; Lee JY; Park SR; Kim YJ; Hwang IG; Kyun Bae W; Byun JH; Kim JS; Kang EJ; Lee J; Shin SJ; Chang WJ; Kim EO; Sa JK; Park KH
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485184
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
Aygun B; Lane A; Smart LR; Santos B; Tshilolo L; Williams TN; Olupot-Olupot P; Stuber SE; Tomlinson G; Latham T; Ware RE;
Lancet Haematol; 2024 Apr; ():. PubMed ID: 38701812
[TBL] [Abstract][Full Text] [Related]
17. VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial.
Coffman-D'Annibale K; Myojin Y; Monge C; Xie C; Hrones DM; Wood BJ; Levy EB; Kleiner D; Figg WD; Steinberg SM; Redd B; Greten TF
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38184304
[TBL] [Abstract][Full Text] [Related]
18. A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
Juric D; Barve M; Vaishampayan U; Roda D; Calvo A; Jañez NM; Trigo J; Greystoke A; Harvey RD; Olszanski AJ; Opyrchal M; Spira A; Thistlethwaite F; Jiménez B; Sappal JH; Kannan K; Riley J; Li C; Li C; Gregory RC; Miao H; Wang S
Cancer Med; 2024 Mar; 13(5):. PubMed ID: 38501219
[TBL] [Abstract][Full Text] [Related]
19. First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
Yarchoan M; Powderly JD; Bastos BR; Karasic TB; Crysler OV; Munster PN; McKean MA; Emens LA; Saenger YM; Ged Y; Stagg R; Smith S; Whiting CC; Moon A; Prasit P; Jenkins Y; Standifer N; Dubensky TW; Whiting SH; Ulahannan SV
Cancer Res Commun; 2024 Apr; 4(4):1100-1110. PubMed ID: 38551394
[TBL] [Abstract][Full Text] [Related]
20. First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial.
Morscher RJ; Brard C; Berlanga P; Marshall LV; André N; Rubino J; Aerts I; De Carli E; Corradini N; Nebchi S; Paoletti X; Mortimer P; Lacroix L; Pierron G; Schleiermacher G; Vassal G; Geoerger B
Eur J Cancer; 2021 Nov; 157():268-277. PubMed ID: 34543871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]